SILK ROAD MEDICAL INC (SILK) Stock Price, Quote, News and Overview
NASDAQ:SILK - Nasdaq - US82710M1009 - Common Stock - Currency: USD
SILK Quote, Performance and Key Statistics
27.49
-0.01 (-0.04%)
The current stock price of SILK is 27.49 USD. In the past month the price increased by 1.36%. In the past year, price increased by 74.98%.
SILK Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
| ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
| BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
| SYK | STRYKER CORP | 31.4 | 145.92B | ||
| MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
| BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
| IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
| DXCM | DEXCOM INC | 53.81 | 34.68B | ||
| RMD | RESMED INC | 26.21 | 34.03B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Related stock screener links
About SILK
Company Profile
Silk Road Medical, Inc. engages in the development and manufacturing of medical devices to treat neurovascular diseases. The company is headquartered in Sunnyvale, California and currently employs 474 full-time employees. The company went IPO on 2019-04-04. The firm has developed an approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. Its product portfolio consists of five single-use components: ENROUTE Transcarotid Neuroprotection System, ENROUTE Transcarotid Stent System, ENHANCE Transcarotid Peripheral Access Kit, ENROUTE 0.014'' Guidewire and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter. The company manufactures ENROUTE NPS and ENROUTE NPS PLUS, or its ENROUTE NPS products, at its facilities in Sunnyvale, California and Plymouth, Minnesota. These facilities provide an aggregate of over 35,000 square feet of space for its production and distribution operations.
Company Info
SILK ROAD MEDICAL INC
1213 Innsbruck Dr
Sunnyvale CALIFORNIA 94089 US
CEO: Erica J. Rogers
Employees: 474
Company Website: https://silkroadmed.com/
Phone: 16505669060
SILK ROAD MEDICAL INC / SILK FAQ
What is the stock price of SILK ROAD MEDICAL INC today?
The current stock price of SILK is 27.49 USD. The price decreased by -0.04% in the last trading session.
What is the ticker symbol for SILK ROAD MEDICAL INC stock?
The exchange symbol of SILK ROAD MEDICAL INC is SILK and it is listed on the Nasdaq exchange.
On which exchange is SILK stock listed?
SILK stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SILK ROAD MEDICAL INC stock?
13 analysts have analysed SILK and the average price target is 22.54 USD. This implies a price decrease of -18% is expected in the next year compared to the current price of 27.49. Check the SILK ROAD MEDICAL INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SILK ROAD MEDICAL INC worth?
SILK ROAD MEDICAL INC (SILK) has a market capitalization of 1.12B USD. This makes SILK a Small Cap stock.
How many employees does SILK ROAD MEDICAL INC have?
SILK ROAD MEDICAL INC (SILK) currently has 474 employees.
What are the support and resistance levels for SILK ROAD MEDICAL INC (SILK) stock?
SILK ROAD MEDICAL INC (SILK) has a support level at 27.21 and a resistance level at 27.51. Check the full technical report for a detailed analysis of SILK support and resistance levels.
Is SILK ROAD MEDICAL INC (SILK) expected to grow?
The Revenue of SILK ROAD MEDICAL INC (SILK) is expected to grow by 16.35% in the next year. Check the estimates tab for more information on the SILK EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SILK ROAD MEDICAL INC (SILK) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SILK, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SILK, evaluating the profitability, health, valuation and growth aspects
- SILK ROAD MEDICAL INC (SILK) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SILK ROAD MEDICAL INC (SILK) Sales and EPS estimates to see what analysts future expectations are.
- SILK ROAD MEDICAL INC (SILK) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SILK ROAD MEDICAL INC (SILK) Insider and Institutional Ownership to learn about the owners and their transactions.
- SILK ROAD MEDICAL INC (SILK) Stock Chart to make your own analysis
- SILK ROAD MEDICAL INC (SILK) Latest news and press-releases to stay up to date.
Does SILK ROAD MEDICAL INC (SILK) stock pay dividends?
SILK does not pay a dividend.
When does SILK ROAD MEDICAL INC (SILK) report earnings?
SILK ROAD MEDICAL INC (SILK) will report earnings on 2024-11-06, after the market close.
What is the Price/Earnings (PE) ratio of SILK ROAD MEDICAL INC (SILK)?
SILK ROAD MEDICAL INC (SILK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.44).
SILK Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to SILK. When comparing the yearly performance of all stocks, SILK is one of the better performing stocks in the market, outperforming 90.01% of all stocks.
SILK Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SILK. The financial health of SILK is average, but there are quite some concerns on its profitability.
SILK Financial Highlights
Over the last trailing twelve months SILK reported a non-GAAP Earnings per Share(EPS) of -1.44. The EPS decreased by -2.13% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.96% | ||
| ROE | -36.55% | ||
| Debt/Equity | 0.49 |
SILK Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 49% to SILK. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of -3.77% and a revenue growth 16.35% for SILK